Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate Persistent Asthma”

106 trials

Showing 20 of 106 results

Not applicableWithdrawnNCT02952066
What this trial is testing

Expressions of TRPV1 in Airway of Asthmatics

Who this might be right for
Moderate Persistent AsthmaSevere Persistent AsthmaNodule Solitary Pulmonary+1 more
Lu Yuan Lee
Large-scale testing (Phase 3)Study completedNCT00314574
What this trial is testing

Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

Who this might be right for
Asthma
Genentech, Inc. 850
Post-approval studies (Phase 4)Study completedNCT01476059
What this trial is testing

Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT

Who this might be right for
Asthma
GlaxoSmithKline 472
Post-approval studies (Phase 4)Ended earlyNCT00687531
What this trial is testing

Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)

Who this might be right for
Asthma
Organon and Co 385
Large-scale testing (Phase 3)Study completedNCT00563056
What this trial is testing

An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma

Who this might be right for
Asthma Bronchiale
Mundipharma Research Limited 227
Post-approval studies (Phase 4)Study completedNCT00691873
What this trial is testing

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Who this might be right for
Asthma
University of Mississippi Medical Center 14
Post-approval studies (Phase 4)Ended earlyNCT00442351
What this trial is testing

Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)

Who this might be right for
Asthma
Organon and Co 26
Large-scale testing (Phase 3)Study completedNCT00476268
What this trial is testing

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Who this might be right for
Asthma
Chiesi Farmaceutici S.p.A. 824
Post-approval studies (Phase 4)Study completedNCT00670930
What this trial is testing

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

Who this might be right for
Allergic Asthma
Novartis Pharmaceuticals 36
Large-scale testing (Phase 3)Study completedNCT01340209
What this trial is testing

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

Who this might be right for
Asthma
Boehringer Ingelheim 285
Testing effectiveness (Phase 2)Study completedNCT01696071
What this trial is testing

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Who this might be right for
Asthma
Boehringer Ingelheim 98
Large-scale testing (Phase 3)Study completedNCT01172808
What this trial is testing

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Who this might be right for
Asthma
Boehringer Ingelheim 1,071
Testing effectiveness (Phase 2)Study completedNCT00141791
What this trial is testing

Study Evaluating Etanercept in Moderate to Severe Asthma

Who this might be right for
Asthma
Wyeth is now a wholly owned subsidiary of Pfizer 120
Testing effectiveness (Phase 2)UnknownNCT00859404
What this trial is testing

A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma

Who this might be right for
Asthma
Glenmark Pharmaceuticals Europe Ltd. (R&D) 282
Testing effectiveness (Phase 2)Study completedNCT01437735
What this trial is testing

Dose Finding Study for QAW039 in Asthma

Who this might be right for
Asthma
Novartis Pharmaceuticals 1,043
Large-scale testing (Phase 3)Study completedNCT00401596
What this trial is testing

Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

Who this might be right for
Asthma
Genentech, Inc. 1,899
Testing effectiveness (Phase 2)Study completedNCT01311661
What this trial is testing

Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Who this might be right for
Asthma
Boehringer Ingelheim 206
Large-scale testing (Phase 3)Study completedNCT01511367
What this trial is testing

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

Who this might be right for
Asthma
Mundipharma Research Limited 498
Large-scale testing (Phase 3)UnknownNCT03387241
What this trial is testing

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Who this might be right for
Asthma
Mundipharma (China) Pharmaceutical Co. Ltd 330
Large-scale testing (Phase 3)Study completedNCT00079937
What this trial is testing

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Who this might be right for
Asthma
Novartis Pharmaceuticals 628
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation